Colorado-based Edgewise Therapeutics, a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading.

Australian biotech major CSL Limited (ASX: CSL) subsidiary CSL Behring today announced that it has successfully concluded ...

US generic manufacturer Padagis has received clearance to extend the shelf life of its over-the-counter naloxone nasal spray ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

Swiss pharma giant Novartis (NOVN: VX) today announced the US Food and Drug Administration (FDA) has granted accelerated ...

The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...

North Carolina, USA-based clinical-stage gene therapy company Atsena Therapeutics has announced the successful closing of an ...

Pharmaceuticals will be exempt from the tariffs on imports to the USA that were announced by US President Donald Trump ...

US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

Swiss pharma major Roche (ROG: SIX) said a higher-dose version of its top-selling multiple sclerosis drug Ocrevus ...

Sino-American biotech BeiGene (HKEX: 06160) today revealed it intends to discontinue its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for ...